| 袁丹,李一平,杨淑娟,刘芳,黄晓玲,姚亮,李玲,周玚,叶黎,曾亚莉,梁姝.四川省部分地区HIV-1感染者二线方案抗病毒治疗效果及耐药突变分析[J].Chinese journal of Epidemiology,2023,44(2):276-284 |
| 四川省部分地区HIV-1感染者二线方案抗病毒治疗效果及耐药突变分析 |
| The antiretroviral treatment effect and drug resistance mutation of antiretroviral treatment for HIV-1 infected patients using second-line regimen in some areas of Sichuan Province |
| Received:July 28, 2022 |
| DOI：10.3760/cma.j.cn112338-20220728-00668 |
| KeyWord: 艾滋病病毒 抗病毒治疗 二线方案 耐药突变 |
| English Key Word: HIV Antiretroviral treatment Second-line regimen Drug resistance mutation |
| FundProject:四川省卫生与健康委员会科研课题（20PJ121）；四川省科学技术厅科研课题（2020YJ0449）；国家科技重大专项（2017ZX10201101） |
| Author Name | Affiliation | E-mail | | Yuan Dan | Center for AIDS/STD Control and Prevention, Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610044, China | | | Li Yiping | Center for AIDS/STD Control and Prevention, Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610044, China | | | Yang Shujuan | West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610044, China | | | Liu Fang | Chengdu Center for Disease Control and Prevention, Chengdu 610041, China | | | Huang Xiaoling | Yibin Center for Disease Control and Prevention, Yibin 644002, China | | | Yao Liang | Butuo County People's Hospital, Butuo 616350, China | | | Li Ling | Center for AIDS/STD Control and Prevention, Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610044, China | | | Zhou Chang | Center for AIDS/STD Control and Prevention, Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610044, China | | | Ye Li | Center for AIDS/STD Control and Prevention, Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610044, China | | | Zeng Yali | Center for AIDS/STD Control and Prevention, Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610044, China | | | Liang Shu | Center for AIDS/STD Control and Prevention, Sichuan Provincial Center for Disease Control and Prevention, Chengdu 610044, China | liangshu523@163.com |
|
| Hits: 2763 |
| Download times: 850 |
| Abstract: |
| 目的 分析四川省部分地区接受一线方案并发生耐药的HIV-1感染者更换二线方案后抗病毒治疗（ART）效果及耐药突变。方法 采用队列研究方法，2019年1月1日至2021年12月31日对接受一线方案发生耐药的HIV-1感染者随访2年，采用χ2检验分析观察终点CD4+T淋巴细胞（CD4）计数、病毒载量（VL）变化及耐药突变情况的差异，使用多因素logistic回归模型分析更换二线方案且依从性较好的HIV-1感染者ART效果的影响因素。结果 共招募HIV-1感染者737例，在持续保持较好依从性的情况下，及时更换二线方案HIV-1感染者持续CD4计数>200个/μl和持续病毒抑制的比例较高（P<0.05），其中基线不同耐药程度HIV-1感染者持续CD4计数>200个/μl和持续VL<200拷贝数/ml（持续病毒抑制）的比例差异无统计学意义（P>0.05）。更换二线方案后，部分蛋白酶抑制剂和非核苷类反转录酶抑制剂的耐药突变位点分别呈上升和下降趋势（P<0.05）。多因素logistic回归分析结果显示，在更换二线方案且依从性较好的HIV-1感染者中，未持续病毒抑制的影响因素包括母婴传播是异性性传播感染的3.01（95%CI：1.29~7.00）倍、未及时更换二线方案是及时更换二线方案的2.55（95%CI：1.41~4.62）倍、CRF85_BC亚型是CRF01_AE亚型的3.32（95%CI：1.49~7.42）倍。结论 一线方案耐药差异不影响更换二线方案后的四川省HIV-1感染者ART效果；及时更换二线方案并保持良好依从性，有助于提高HIV-1感染者免疫水平和持续保持较低VL水平。母婴传播、未及时更换二线方案和感染CRF85_BC亚型是HIV-1感染者更换二线方案后影响ART成功的危险因素。 |
| English Abstract: |
| Objective To analyze the treatment effect and drug resistance mutation of HIV-1 infected patients who changed to the second-line antiretroviral treatment regimen after they had developed drug-resistance with first-line antiretroviral treatment regimen in some areas of Sichuan Province. Methods Using the cohort study method, the patients who had developed drug resistance with the first-line regimen were followed up for two years from 1 January 2019 to 31 December 2021.The changes of CD4+T lymphocytes (CD4) counts and viral load (VL) at the endline and the detection of drug-resistant mutation sites were analyzed using the chi-square test. Multivariate logistic regression model was used to analyze the influencing factors of antiretroviral treatment effect in patients who had good compliance after switching to the second-line regimen.Results A total of 737 patients were recruited. Among the cases with continuous good compliance, those who timely changed to the second-line regimen had higher proportion of maintaining continuous CD4 >200 cells/μl and sustained virus inhibition (P<0.05). Among the patients with different levels of drug resistance at baseline, there was no significant difference in continuous CD4 >200 cells/μl and sustained VL <200 copies/ml (P>0.05). After changing to the second-line regimen, the drug-resistant mutation sites of some protease inhibitors showed an upward trend, while those of the non-nucleoside reverse transcriptase inhibitors showed a downward trend (P<0.05). Multivariate logistic regression analysis showed that, among patients who had good compliance and who had switched to the second-line regimen, mother-to-child-transmitted patients had 3.01 times higher risk than heterosexual sexually transmitted infection (95%CI:1.29-7.00), failure to change the second-line protocol in time brought 2.55 times higher risk than that of timely changing to the second-line regimen (95%CI:1.41-4.62) and patients who infected with CRF85_BC subtype had 3.32 times higher risk than those infected with CRF01_AE subtype (95%CI:1.49-7.42). Conclusions Difference in the drug resistance levels with the first-line regimen does not affect patients' antiretroviral treatment effect after changing to the second-line regimen in Sichuan Province. Changing to the second-line regimen in time and maintaining good compliance are beneficial to higher immune levels and lower VLs in drug-resistant patients. Among patients who changed to the second-line regimen, mother-to-child transmission, failure to change the second-line program in time, and infection with CRF85_BC virus are risk factors endangering antiretroviral treatment success after changing to the second-line regimen. |
|
View Fulltext
Html FullText
View/Add Comment Download reader |
| Close |
|
|
|